A hybrid ML-PBPK digital twin framework for clinically interpretable readmission risk and drug exposure stratification in diabetes.Model scenario comparison · pk_exposure_auc_24hArea under the curve (AUC), Pharmacokinetics and drug exposure · PDF pp. 21, 30
Characterizing Apixaban Pharmacokinetics Through Physiologically-Based Pharmacokinetic Modeling: Critical Role of Biliary Secretion and Enterohepatic Circulation in Humans.Pharmacokinetic scenario comparison · fractionArea under the curve (AUC), Pharmacokinetics and drug exposure · PDF pp. 4, 7
Osimertinib Optimal Dosing Through Population Pharmacokinetics in Virtual Patients with NSCLC: An Approach Integrating Multiple Studies.Model scenario comparison · plasma_drug_exposurePharmacokinetics and drug exposure · PDF pp. 1
Osimertinib Optimal Dosing Through Population Pharmacokinetics in Virtual Patients with NSCLC: An Approach Integrating Multiple Studies.Model scenario comparison · fraction_within_published_reference_intervalCohort size and coverage, Pharmacokinetics and drug exposure · PDF pp. 10
DigiLoCS: A leap forward in predictive organ-on-chip simulations.Model evaluation · clearancePharmacokinetics and drug exposure · PDF pp. 3
Generating and Modeling Virtual Patient Data from Published Population Pharmacokinetic Analyses: A Vancomycin Case Study.Repeated estimation in virtual population models · population_typical_drug_clearancePharmacokinetics and drug exposure · PDF pp. 7
Human Small Intestinal Tissue Models to Assess Barrier Permeability: Comparative Analysis of Caco-2 Cells, Jejunal and Duodenal Enteroid-Derived Cells, and EpiIntestinal TM Tissues in Membrane-Based Cultures with and Without Flow.Model input benchmark · fractionPharmacokinetics and drug exposure · PDF pp. 14
Improving Individualized Salbutamol Treatment: A Population Pharmacokinetic Model for Oral Salbutamol in Virtual Patients.Baseline pharmacokinetic model comparison · fold_deviation_within_twofoldPharmacokinetics and drug exposure · PDF pp. 7
Integration of in vitro data from three dimensionally cultured HepaRG cells and physiologically based pharmacokinetic modeling for assessment of acetaminophen hepatotoxicity.Pharmacokinetic model benchmark · peak_concentrationArea under the curve (AUC), Pharmacokinetics and drug exposure · PDF pp. 24
Integration of in vitro data from three dimensionally cultured HepaRG cells and physiologically based pharmacokinetic modeling for assessment of acetaminophen hepatotoxicity.In vitro to in vivo extrapolation · peakPharmacokinetics and drug exposure · PDF pp. 26
Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations.Virtual population exposure comparison · fold_changePharmacokinetics and drug exposure · PDF pp. 3
Modelled plasma concentrations of pemafibrate with co-administered typical cytochrome P450 inhibitors clopidogrel, fluconazole or clarithromycin predicted by physiologically based pharmacokinetic modelling in virtual populations.Model evaluation · fold_deviation_within_twofoldPharmacokinetics and drug exposure, Prediction or fitting error · PDF pp. 8
Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation.Virtual population pharmacokinetic evaluation · meanPharmacokinetics and drug exposure · PDF pp. 10
Insights into in vitro biokinetics using Virtual Cell Based Assay simulations.Model scenario comparison · compartment_chemical_concentrationMolecular abundance and counts, Pharmacokinetics and drug exposure · PDF pp. 13
PBPK and its Virtual Populations: the Impact of Physiology on Pediatric Pharmacokinetic Predictions of Tramadol.Model evaluation · qualitative_agreementPharmacokinetics and drug exposure · PDF pp. 5
Assessment of Bioequivalence of Weak Base Formulations Under Various Dosing Conditions Using Physiologically Based Pharmacokinetic Simulations in Virtual Populations. Case Examples: Ketoconazole and Posaconazole.Model scenario comparison · peakArea under the curve (AUC), Pharmacokinetics and drug exposure · PDF pp. 6
Virtual Cell Based Assay simulations of intra-mitochondrial concentrations in hepatocytes and cardiomyocytes.Model evaluationMolecular abundance and counts, Pharmacokinetics and drug exposure · PDF pp. 6
Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs.Model scenario comparison · bioequivalence_interval_threshold_attainmentArea under the curve (AUC), Pharmacokinetics and drug exposure · PDF pp. 2
Analysing the role of UVB-induced translational inhibition and PP2Ac deactivation in NF-κB signalling using a minimal mathematical model.Model evaluation · elimination_half_lifePharmacokinetics and drug exposure · PDF pp. 2
In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.Mechanism removal · fractionPharmacokinetics and drug exposure · PDF pp. 10, 11